Monthly Prescribing Reference

Erzofri Now Available for Schizophrenia, Schizoaffective Disorder

The extended-release delivery coupled with the 351mg dose allows for single-dose initiation. Erzofri ® (paliperidone palmitate) extended-release injectable suspension is now available for the ...
JD Supra

Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment

In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
Business Wire

Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY ® from Perseris

MONTPELLIER, France--(BUSINESS WIRE)--New data presented by Teva at ECNP 2024 * demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris ® (RBP-7000) provided the most ...
Morningstar

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

UZEDY® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY ...